Hospira Articles
Hospira returns to profit, with EPS beating expectations
8 November 2012
Hospira to acquire Orchid API production and R&D facility
30 August 2012
News briefs: Drug majors eyeing Strides Arcolab unit; Astellas invests in oncology facility
20 August 2012
Hospira 2nd-qtr income falls 45%, hit by costs
2 August 2012
Hospira returns Posidur rights to DURECT
2 April 2012
US FDA acts on cancer drugs shortages; move applauded by GPhA
22 February 2012
Hospira challenges Cubist patents on Cubicin
10 February 2012
Hospira progresses biosimilar Epogen
11 January 2012
Hospira gains rights to commercialize Kiadis Pharma’s ATIR in Europe, Africa and Asia-Pacific
5 January 2011
Roche hires new head of inflammation/virology research; Hospira recruits former Actavis exec; Alcon names new CFO
5 October 2010
Sanofi facing generic Taxotere competition in USA; first biosimilar cleared in Australia
30 September 2010
Abbott Labs to sell flu vaccine business acquired with Solvay? Hospira buy of Javelin to complete
30 June 2010
Hospira to fund Javelin with $2 million loan, pending outcome of merger deal; signs deal with Durect
8 June 2010
Javelin Pharma rockets as it gets a better offer from Hospira, so ditching deal with Myriad
13 April 2010
Showing 1-30 of 30 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
